Across the pond...Nasdaq: KZIA, page-236

Let's hope they don't make the same mistake in the clinic!

Experimental: Arm II (PI3K gene mutation)Patients receive PI3K inhibitor GDC-0084 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. https://clinicaltrials.gov/ct2/show/NCT03994796

Description of TreatmentPatients will be randomized into one of three groups. Those in Group 1 (CDK gene mutation) will receive abemaciclib orally twice daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Those in Group 2 (PI3K gene mutation) will receive PI3K inhibitor GDC-0084 orally once daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Those in Group 3 (NTRK/ROS1 gene mutation) will receive entrectinib orally once daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. https://www.allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=/Public/News-Genetic-Nov2019